EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Optimal combination of heart and lung dose parameters in radiotherapy for locally advanced non-small cell lung carcinoma: a multicenter retrospective study

Tomohiko Miyazaki iD, Koichi Yasuda iD, Hiroshi Taguchi iD, Hideki Minatogawa iD, Tetsuya Inoue, Rikiya Takashina, Manami Otsuka, Keiji Nakazato, Noriaki Nishiyama iD, Keiji Kobashi iD, Izuru Otake, Jun Sakakibara-Konishi und 4 weitere

Journal of Radiation Research · 24.07.2026 · 67 (4) · 591-599

DOI: 10.1093/jrr/rrag034 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Radiation Research, online erschienen am 14.05.2026. Verfasst von Tomohiko Miyazaki und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Graduate School of Medicine and Faculty of Medicine Hokkaido University, North 15 West 7, Kita-ku, Sapporo, Hokkaid…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Heart, Lung, Lung Neoplasms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to identify the optimal combination of heart and lung dose parameters associated with overall survival (OS) in patients with locally advanced non-small cell lung carcinoma (LA-NSCLC) receiving radiotherapy. Data from 278 patients treated definitively for LA-NSCLC at three institutions between 1 April 2013 and 31 October 2021 were retrospectively analyzed. Lung and heart dose parameters were categorized into high- or low-dose groups based on predefined thresholds for subsequent analysis. Univariable analysis of OS was conducted for all dose group combinations. The combination with the lowest P-value was identified as the most promising and included in the multivariable analysis along with other clinical factors. The combinations of mean heart dose (MHD)/lung V40 (LV40) (‘Vxx’ denotes the percentage of organ volume receiving ≥xx Gy) and heart V5 (HV5)/LV40 yielded the lowest P-values (P = 0.021). The thresholds for these dose parameters were MHD ≤24.4 Gy, HV5 ≤63% and LV40 ≤7.7%, respectively. Multivariable analysis incorporating clinical factors identified age ≥65 years (HR: 2.06, P = 0.002), performance status ≥1 (Hazard ratio [HR]: 1.68, P = 0.024), chemoradiotherapy (HR: 0.28, P < 0.001), current smoking history (HR: 2.21, P < 0.001), gross tumor volume (HR: 1.43, P = 0.007) and the MHD/LV40 combination (HR: 2.35, P = 0.003) as independent prognostic factors. While exploratory, this study highlights the clinical significance of the MHD/LV40 combination as a prognostic factor; integrating these parameters radiotherapy for LA-NSCLC may improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungHeartLungLung NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedDose-Response Relationship, RadiationRadiotherapy DosageRetrospective Studies

Stichwörter der Autor:innen

cardiac toxicityheart doselocally advanced non-small cell lung carcinomamulticenter retrospective studyoverall survivalradiation oncology

Autor:innen und Institutionen

  • Department of Radiation Oncology, Graduate School of Medicine and Faculty of Medicine Hokkaido University, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
  • Department of Radiation Oncology, Hokkaido University Hospital, NHO Hokkaido Cancer Center and Obihiro Kosei Hospital, 2-3-54, Kikusui-4, Shiroishi-ku, Sapporo, Hokkaido 003-0804, Japan.
  • Department of Radiology, Obihiro Kosei Hospital, West 15, South 10, Obihiro, Hokkaido 080-0024, Japan.
  • Department of Medical Physics, Hokkaido University Hospital, North 14 West 5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.
  • Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
  • Department of Respiratory Medicine, Hokkaido University Hospital, North 14 West 5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.

ORCID-Profile: Tomohiko Miyazaki, Koichi Yasuda, Hiroshi Taguchi, Hideki Minatogawa, Noriaki Nishiyama, Keiji Kobashi, Takayuki Hashimoto, Hidefumi Aoyama

Förderung

  • JSPS KAKENHI

Zitieren

APA

Miyazaki, T., Yasuda, K., Taguchi, H., Minatogawa, H., Inoue, T., Takashina, R., Otsuka, M., Nakazato, K., Nishiyama, N., Kobashi, K., Otake, I., Sakakibara-Konishi, J., Oizumi, S., Kikuchi, H., Hashimoto, T., & Aoyama, H. (2026). Optimal combination of heart and lung dose parameters in radiotherapy for locally advanced non-small cell lung carcinoma: a multicenter retrospective study. Journal of Radiation Research, 67(4), 591-599. https://doi.org/10.1093/jrr/rrag034

Vancouver

Miyazaki T, Yasuda K, Taguchi H, Minatogawa H, Inoue T, Takashina R, et al. Optimal combination of heart and lung dose parameters in radiotherapy for locally advanced non-small cell lung carcinoma: a multicenter retrospective study. Journal of Radiation Research. 2026;67(4):591-599. doi:10.1093/jrr/rrag034

BibTeX
@article{Miyazaki2026,
  author = {Miyazaki, Tomohiko and Yasuda, Koichi and Taguchi, Hiroshi and Minatogawa, Hideki and Inoue, Tetsuya and Takashina, Rikiya and Otsuka, Manami and Nakazato, Keiji and Nishiyama, Noriaki and Kobashi, Keiji and Otake, Izuru and Sakakibara-Konishi, Jun and Oizumi, Satoshi and Kikuchi, Hajime and Hashimoto, Takayuki and Aoyama, Hidefumi},
  title = {Optimal combination of heart and lung dose parameters in radiotherapy for locally advanced non-small cell lung carcinoma: a multicenter retrospective study},
  journal = {Journal of Radiation Research},
  year = {2026},
  volume = {67},
  number = {4},
  pages = {591--599},
  doi = {10.1093/jrr/rrag034}
}
Kostenlos starten →